Impact of the C2/C6 ratio of high-molecular-weight hydroxyethyl starch on pharmacokinetics and blood coagulation in pigs by Schramm, S.
UNIVERSITÉ DE LAUSANNE - FACULTÉ DE BIOLOGIE ET DE MÉDECINE 
DEPARTEMENT DE MEDECINE 
DIVISION SPECIALISEE DE PHARMACOLOGIE ET TOXICOLOGIE CLINIQUES 
Impact of the C2/C6 Ratio of High-Molecular-Weight Hydroxyethyl Starch on 
Pharmacokinetics and Blood Coagulation in Pigs 
THESE 
préparée sous la direction du Professeur Donat R. Spahn jusqu'en octobre 2006, 
puis sous la direction du Docteur Thierry Buclin, Privat Docent 
et présentée à la Faculté de biologie et de médecine de 
l'Université de Lausanne pour l'obtention du grade de 
DOCTEUR EN MEDECINE 
par 
Sebastian SCHRAMM 
Médecin diplômé d'Allemagne 
Originaire de Erlangen/Allemagne 
Lausanne 
2008 
') 
) 
1 
2 
Rapport de synthèse 
Contexte: l'hydroxyéthylamidon (HEA) est largement utilisé comme expanseur 
volémique en anesthésiologie et réanimation. Cependant, cette classe de produits 
perturbe le system de la coagulation. Des améliorations restent possibles dans le choix 
de la combinaison optimale de poids moléculaire, de degré de substitution en radicaux 
éthyle et de localisation de ces radicaux sur le squelette glucidique des polymères, afin 
d'optimiser leur efficacité et leur tolérance. L'HEA de poids moléculaire élevé et 
faiblement substitué n'affecte pas plus la coagulation sanguine que de l'HEA de bas 
poids moléculaire faiblement substitué. Nous examinons in vivo l'effet d'un abaissement 
du rapport C2/C6 sur les caractéristiques pharmacocinétiques et l'impact sur la 
coagulation sanguine d'un HEA de haut poids moléculaire faiblement substitué. 
Matériels et méthode: nous comparons dans une étude prospective, randomisée et 
parallèle l'HEA 650/0.42/2.8 avec l'HEA 650/0.42/5.6 auprès de 30 cochons. Avant, 
pendant et jusqu'à 630 minutes après une perfusion de 30 ml/kg d'HEA, des · 
échantillons sanguins ont été collectés pour mesurer les concentrations d'HEA, les tests 
de coagulation plasmatique classiques et la coagulation sanguine par 
thrombélastographie (TEG®, Haemoscope Corporation, Niles, Il, U.S.). Les paramètres 
pharmacocinétiques ont été estimés en adaptant un modèle à deux compartiments. 
Résultats: la constante d'élimination est de 0.009 ± 0.001 (min-1) pour l'HEA 
650/0.42/2.8 et 0.007 ± 0.001 (min-1) pour l'HEA 650/0.42/5.6 (p<0.001 ); la surface sous 
la courbe de concentration est de 1374 ± 340 min*g/L pour l'HEA 650/0.42/2.8 et 1697 ± 
411 min*g/L pour l'HEA 650/0.42/5.6 (p=0.026). Les concentrations mesurées d'HEA ne 
montrent pas de différence entre l'HEA 650/0.42/2.8 et l'HEA 650/0.42/5.6. Les deux 
solutions d'HEA affectent de façon identique la coagulation sanguine: l'index de 
coagulation thrombélastographique diminue pareillement à la fin de la perfusion d'HEA 
650/0.42/2.8 et d'HEA 650/0.42/5.6 (p=0.29). De même, le temps de thromboplastine 
partielle activée et le temps de prothrombine augmentent de manière similaire pour 
l'HEA 650/0.42/2.8 et l'HEA 650/0.42/5.6 (p=0.83). 
Conclusion: la réduction du rapport C2/C6 de l'HEA de poids moléculaire élevé et 
faiblement substitué aboutit à une élimination légèrement accélérée d'HEA. Cependant, 
elle ne modifie pas l'effet perturbateur sur la coagulation. 
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Hydroxyethyl Starch on Pharmacokinetics and Blood 
Coagulation in Pigs 
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Background: High-molecular-weight, low-substituted hy-
drol'>.}'ethyl sta1·ch (HES) may not affect blood coagulation more 
than low-molecular-weight, low-substituted HES. The authors 
assessed in vivo the effect of a lowered C2/C6 ratio on pharma-
cokinetic charactel'istics and the impact on blood coagulation 
of high-molccular-weight, low-substituted HES. 
Metbods: A prospective, randomized, parallel study in 30 pigs 
compal'Cd HES 650/0.'!2/2.8 with HES 650/0.42/5.6. Before, dur-
ing, and after infusion of 30 ml/kg body weight IIES, blood 
samples were collected over 630 min to measure HES concen-
trations and plasmatic coagulation and to assess blood coagu-
lation in whole blood by Thrombelastography'"' (TEG"'; llaemo-
scope Corporation, Niles, IL). Pharmacokinetic pammete1·s 
were estimated using a two-compartment model. 
Results: The elimination constant was 0.009 ± 0.001 min- 1 
fot• HES 650/0.42/2.8 and 0.007 ± 0.001 min- 1 fot· HES 650/0.42/ 
5.6 (P < 0.001); the area undcr the plasma eoncentt·ation-titne 
Clll'Ve was 1,374 ± 340 min· g/l for HES 650/0.42/2.8 and 1,697 
± 411 min· g/l foi· HES 650/0.42/5.6 (P = 0.026). The measured 
plasma HES concentrations were not diffcrent between HES 
650/0.42/2.8 and HES 650/0.42/5.6. Both IIES solutions equally 
affected blood coagulation: Tlu·ombclastographic coagulation 
index decreased similarly at the end of infusion of HES 650/ 
0.42/2.8 and at the end of infusion of HES 650/0.42/5.6 (P = 
0.293). Also, activated partial thromboplastin and protlu·ombin 
titnes increased similarly for HES 650/0.42/2.8 and HES 650/ 
0.42/5.6 (P = 0.831). 
Conclusion: Reducing the C2/C6 mtio in high-molccular, low-
substituted HES solutions results in a slightly faster HES elimi-
nation. However, the blood coagulation compromising effect 
was unaffected. 
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FOR almost four decades, hydroxyethyl starches (HESs) 
are known as effective plasma volume expanders and 
have therefore found widespread dinical application as 
plasma substitutes. 1- 3 HESs are high polymeric glucose 
compounds obtained by hydrolysis and subsequent hy-
dro),,-yethylation from the waxy maize starch amylopec-
tin. 4 The physicochemical characteristics of HESs are 
detennined by their mean molecular weight; by their 
molar substitution ratio, which expresses the average 
number of hydroxyethyl groups per unit of glucose; and 
by their C2/C6 ratio, which refers to the preferential 
hydroxyethylation site at the glucose subunit carbon 
atoms.5 
The dinical use of HES is limited mainly by their 
affection of hemostasis, which is detectable by impaired 
platelet function6 as well as a type I von \Villebrand-like 
syndrome with reduced levels of factor VIII (FVIII) and 
von Willebrand factor (vWF), observed to a greater ex-
tent than expected from the hemodilution effect.4 '7 - 9 In 
addition, altered coagulation was repo1ted by Throm-
belastography® (TEG®; Haemoscope Corporation, Niles, 
IL). 10' 11 The extent of such alterations has classically 
been relatecl to the molecular weight or molar substitu-
tion of the used HES solutions.4•8 •9 •12 Butin most studies, 
a reduction of molecular weight was followed by a 
concomitant reduction of molar substitution and was 
therefore not assessed specifically. In contrast, a recent 
study has shown that the coagulation compromising 
effects of high-molecular-weight, low-substituted HES 
was not greater than those of low-molecular-weight, 
low-substituted HES 130/0.42.13 Such findings question 
the assumption that molecular weight may be the only 
factor determining coagulation-compromising effects of 
HES. 
The C2/C6 ratio of HES solutions is often not specified 
in publishecl studies or varies between tested solutions. 
A study in healthy volunteers showed that medium-1110-
lecular-weight HES with a high C2/C6 ratio was elimi-
nated more slowly than HES with a low C2/C6 ratio, but 
the impact on blood coagulation was not assessed. 14 In 
a recent in vitro study, a reduction of the C2/C6 ratio to 
2.7 of high-molecular-weight, low-substituted HES (HES 
700/0.42/2.7) was shown to minimize the effect on 
human blood coagulation as assessed by TEG® .15 How-
ever, a low C2/C6 ratio may shorten the elimination 
half-life, and could therefore be disadvantageous in 
terms of diminished volume-expanding effect. 14 
This in vivo study in pigs was performed to define the 
C2/C6 RATIO OF HES AND BLOOD COAGULATION 
pharmacokinetics and the impact on blood coagulation 
as well as hemoglobin and albumin concentrations as 
surrogates for hemodilutional effect of a high-molecular-
weight (650 kd), low-substituted (0.42) HES with a low 
C2/C6 ratio of 2.8 (HES 650/0.42/2.8). We compared 
this solution with HES 650/0.42/5.6 to assess the specific 
effect of C2/C6 ratio. 
Materials and Methods 
The animal experiments were performed according to 
the guidelines of the Swiss Federal Veterinary Office. 
The protocol was approvecl by the Veterinary Office of 
the Canton de Vaud, Switzerland. The study group con-
sisted of 30 pigs with a mean body weight of 41.2 ± 3.6 
(SD) kg. The pigs were fasted overnight but allowed free 
access to water. 
Animal Preparation 
The evening before the stucly, the pigs were separated 
from their group and premedicatecl with 150 µ..g 
clonicline (Boehringer Ingelheim [Schweiz] GmbH, 
Basel, Switzerlancl) via intramuscular injection. Before 
the transportation, a close of 0.5 mg/kg body weight 
(BW) midazolam (Roche Pharma AG, Reinach, Switzer-
lancl) was aclministerecl intramuscularly. llpon anival in 
the laboratory, the animais receivecl intramuscular pre-
meclication of 1 mg/kg BW miclazolam (Roche Pharma 
AG) and 20 mg/kg BW ketamine (Veterinaria AG, Zurich, 
Switzerlancl). Once sedation was obtainecl, anesthesia 
was inducecl by administration of 3% halothane (Drager, 
Luebeck, Germany) by mask, followed by tracheal intu-
bation. 
Controllecl ventilation was performed. An end-ticlal vol-
ume of 10 -13 ml/kg BW and a ventilation rate of 13-
18/min were acljustecl to maintain partial pressure of 
carbon dioxicle at 35- 40 mmHg before the onset of the 
protocol (Ventilator Drager Sulla 909 V; Drager). The 
inspirecl oxygen fraction was monitored and maintained 
at 1.0 duting surgical instmmentation and decrea.sed to 
0.4 (air- mrygen mixture) cluring the experimental pro-
tocol. The ear vein was cannulated (18-gauge cannula). 
Anesthesia was now switched to a total intravenous 
anesthesia using 5-10 mg· kg BW- 1 • h- 1 propofol (B. 
Braun Medical AG, Emmenbruecke, Switzerlancl), 0.6 ml 
· kg- 1 • h- 1 miclazolam (Roche Pharma [Schweiz] AG, 
Reinach, Switzerland), and 25 µ..g ·kg BW- 1 • h- 1 fent-
anyl (Sintetica S.A., Menclrisio, Switzerlancl) during sur-
gical instrumentation. Fentanyl closing was lowered after 
the surgical instrumentation to a close of 3-7 µ..g · kg 
BW- 1 • h - i, accorcling to the requirements of each 
inclividual pig. NaCl 0.9% solution was infused in a dos-
age of 10 ml · kg - l • h - l cluring the en tire period of 
anesthesia. Glucose 20% solution was administered ac-
cording to the requirements of each incliviclual pig to 
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keep the blood glucose concentration in a range of 
3.7-5.2 111M. 
A catheter '>vas placed into the right interna! jugular 
vein for administration of the intravenous anesthesia. 
Another catheter was placed in the ipsilateral carotid 
artery for blooc! withdrawal for laboratory measure-
ments, arterial blood gas analyses, and continuons mea-
surement of arterial bloocl pressure. In the contralateral 
interna! jugular vein, a catheter was inserted for HES 
administration and later on for 20% glucose administra-
tion. Further monitoring of the animals includec! contin-
uous three-lead elcctrocardiogram, heart rate reading, 
and continuous body temperature monitoring by a 
probe inserted in the esophagus. In addition, a transmu-
ral bladder catheter was insertecl performing a minilapa-
rotomy. Sheets, a ventilator, and ice were used if neces-
sary to keep body temperature at 38° ± 1 °C. 
HES Synthase 
Thin-boiling waxy maize starch was suspenclecl in wa-
ter, activated by means of sodium hydroxide, and al-
lowed to react with ethylene oxide for 2 h at 40°C. The 
amounts of waxy maize starch and ethylene oxide were 
chosen to yielcl HES with a molar substitution of 0.42. 
HES C2/C6 ratios of 2.8 and 5.6 were obtained by chang-
ing the quantities of sodium hyclroxide during hydroxy-
ethylation. The raw HES species were hydrolyzed by 
hydrochloric acicl to a molecular weight of 650 kcl, 
treated with activatecl carbon, purified by ultrafiltration, 
and dilutecl to a final concentration of 6% (wt/vol) in 
isotonie saline, filled in glass bottles of 500 ml each and 
heat-sterilizecl at 121 °C for 20 min. 
HES Characterization 
The mean weight average molecular weight (MWw) of 
HES was determined by gel permeation chromatogra-
phy/multiangle laser light scattering (GPC-MALLS; Wyatt 
Technology, Wolcle1t, Germany) at a flow rate of 1 ml/ 
min in a 70 mM phosphate buffer pH 7.0 using serial GPC 
columns HEMA Bio 40, 100, and 1,000 (PSS, Mainz, 
Gennany). Molecular weight was calculated using AS-
TRA Software (Wyatt Technology). The weight averaged 
molecular weight, calculated as MWw = 2:1 (M12 N;)/:Si 
(M1Ni), gives higher statistical weight to larger mole-
cules. In contrast, the number averagecl molecular 
weight, calculated as MWn = 2:1 (MiNi)/2:1 N;, gives equal 
statistical weight to each molecule. The polydispersity 
index MWw/MWn clescribes the distribution of the mo-
lecular weights, with values near 1 for a narrow distri-
bution. 
Molar substitution was determined by gas chromatog-
raphy after transforming hydroxyethyl groups into ethyl 
iodine by hydrioclic acid in the presence of adipic acid 
using a gas chromatograph Perkin Elmer Autosystem 
(Boston, MA). The C2/C6 ratio was cletermined after 
hydrolysis of HES by sulfuric acid and gas chromato-
444 
Table 1. HES Characteristics 
HES 650/0.42/2.8 HES 650/0.42/5.6 
ln vitro molecular weight, kd 
Molar substitution 
C2/C6 ratio 
Concentration, % 
641 
0.42 
2.8 
6 
647 
0.42 
5.6 
6 
Physiochemical characteristics of the two hydroxyethyl starches (HESs). 
graphie separation of the sialylated hyclroxyethylated 
glucose derivatives using a gas chromatograph Carlo 
Erba Mega 5300 (Milano, Italy). In table 1, the physio-
chemical parameters of the investigated HES solutions 
are shown. 
Experimental Protocol 
The animais were randomized into two groups of 15 
pigs each, receiving either 6% HES 650/0.42/2.8 (test 
group) or 6% HES 650/0.42/5.6 (reference solution). The 
treatments were strictly blinded over the whole study 
period. Unblinding was delayed until the data analysis 
was finalized. After completion of ail surgical prepara-
tions, the first of 13 blood samples were taken for base-
line values using citrated blood containers. Directly after 
baseline blood sampling, the administration of the solu-
tion started. A top-load dose of 30 ml/kg BW was infused 
over exactly 30 min. During and after the infusion, blood 
withdrawals were performed at 10, 20, 30, 40, 50, 60, 
90, 120, 150, 270, 390, 510, and 630 min after the start 
of the infusion. 
Laborato1J1 111.easurements 
Hemoglobin Concentration. Arterial blood samples 
were collected using hepal'inized syringes (BD Preset; 
BD Vacutainer Systems, Plymouth, United Kingdom). 
Hemoglobin concentration was determined immediately 
after collection using the Rapidlab 865 analyzer (Bayer 
Vital GmbH, Fernwald, Germany). 
Albmnin Concentration. Albumin concentration 
was measured by means of enzyme-linked immunosor-
bent assay (ELISA) using the sandwich technique. ELISA 
!dt starter accessory package E 101 (Bethyl, Montgom-
ery, TX) was combined with the Pig Albumin ELISA 
Quantification Kit El00-110 (Bethyl). Briefly, coating of 
the wells with the capture antibody and blocking was 
effected before the increasingly diluted plasma samples 
were incubated for 60 min. These were linked witll 
antibody conjugate for another 60 min. In a last step, 
enzyme-substratc solution was addcd and quantification 
was measured by means of calorimetry at 490 11111 
(EI.X808; BioWhittaker Inc., Walkcrsville, MD). 
Thrombelastography@ Analysis. Citrated whole 
blood was used to issue a Thrombelastogram <ID. An initial 
incubation for 1 h in a 3 7°C water bath was performed 
with tlle citrated whole blood samples, 16 followed by 
blood recalcification and TEG® measurements using two 
~esthesJology, V ,107, No 3, Sep 2007 
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computerizecl Thrombelastography"" coagulation analyzers 
5000 (IIaemoscope Corporation) with two channels for 
each analyzer. Four samples were analyzed at a time with a 
randomly chosen channel sequence. The following TEG@ 
parameters are reported: reaction timc (r time), coagula-
tion time (k tilne), maximal amplitude, angle a, elastic 
shear modulus, and coagulation index.16•17 
For further laborato1y measurements, blood samples 
were immediately centrifuged at 3,000 rpm for 15 min at 
4°C for separation of plasma and blood cellular compo-
nents (Rotanta/RP; Hettich, Bach, Switzerland). 
Plasn1a Coagulation. Prothrombin time and activated 
partial thromboplastin time (aPTT) were determined on an 
automated coagulation analyzer (BCS; Dacie Behring, Mar-
burg, Germany) using a prothrombin time reagent contain-
ing recombinant tissue factor (Innovin; Dacie Behring) and 
an aPTT reagent containing ellagic acid (Actin FS; Dacie 
Behring), respectively. Functional activity of vWF was cle-
te1mined in a commercial tistocetin-cofactor assay (vWF 
RCA; Dade Behring) on an automated coagulation analyzer 
(BCS). Bliefly, vWF activity was assessed by the ability to 
agglutinate fixcd human platelets in the presence of risto-
cetin. Agglutination was measurecl turbidimettie<ùly using 
the coagulation analyzer. FVII.1 was assessed functionally 
using FVI.II-deficient plasma according to the manufactur-
er's instructions (Dacie Behling). 
HES Concentration. Hydro:i-.-yethyl starch concentra-
tion was quantified after extraction from plasma and 
hydrolysis to glucose monomers. Briefly, plasma samples 
(1 ml) were incubated at 100°C for 60 min after addition 
of 0.5 ml KOH solution 35% (wt/wt) (Fluka, Buchs, 
Switzerlancl). I-IES was precipitated by aclding of 10 ml 
ice-cold absolute ethanol (Fluka) to the supernatant of 
the reaction mixture and acid hydrolyzecl in 2N HCl 
(Fluka) for 60 min at 100°C. Glucose determination was 
performed using an enzymatic test kit based on hexoki-
nase/glucose 6-phosphatase (Boehringer Mannheim, 
Darmstadt, GermanJi). For determination of HES molec-
ular weight, plasma proteins were climinated by trichlo-
roacetic acid precipitation (6.4% [wt/wt] end concentra-
tion), and neutralized supernatants were analyzed by 
GPC-MALLS at a flow rate of 1 ml/min in 70 mM phos-
phate buffer, pH 7.0, using serial GPC columns HEMA 
Bio 40, 100, and 1,000. 
Pbarmacokinetic Modeling 
Pharmacokinetic parameters were obtained through 
individual fitting of the plasma concentration data with a 
biexponential mode! using the software Kinetica, ver-
sion 4.3 (InnaPhase Corp., Philadelphia, PA). Curve fit-
ting was performed by notùinear regression, using 
weights of l/Y0 bs2 to accommodate for data heterosce-
dasticity. The use of a two-compartment mode! seemed 
appropriate to describe the concentration curves: 
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Fig. 1. Pharmacokinetic modeling. The quality of fit between 
observed hydroxyethyl starch (HES) concentrntion data and 
calculated data was analyzed by linear regression analysis. 
Concentration during infusion 
Concentration after infusion 
--1. e-lqt + i [ 
c (1 - c) 
À1 À, 
where c 1 = relative coefficient for the central compart-
ment, A1 = slope of the distdbution phase, Àz = slope of 
the elimination phase, V1 = volume of the central com-
partment, and R0 = rate of I-IES administration, i.e., the 
dose clivicled by the infusion cluration. A one-compart-
ment mode! showed significant misfit, whereas a three-
compartment mode! seemecl overparameterizecl, with 
high SE and strong intercorrelation values of the esti-
mates. In addition, a visual inspection of diagnostic plots 
such as observecl versus calculated values (fig. 1) and 
residuals versus time (not shown) did not reveal any 
systematic trend suggestive of mode! misfü. Further mac-
roconstants (area under the curve; CL = systemic clear-
ance = ratio of close over area under the curve; t112 = 
tenninal half-life = log2/Àz, cmax = end-of-infusion level) 
and microconstants of the mode! (k12 , k21 , and ke1, i.e., 
transfer constants between compartments and to elimi-
nation) were derived by the Kinetica software using 
standard formulae. 
Statistical AnaZvsis 
Sample size has been cletermined by a power analysis 
based on a previous in vivo study. 13 To obtain a power 
of 80% with an estimated difference between groups of 
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Table 2. Baseline Values 
Body weight, l<g 
Mean arterial blood pressure, 
mm Hg 
Heart rate, beats/min 
Body temperature, 0 c 
Hemoglobin concentration, g/dl 
Albumin concentration, g/1 
Baseline values of the two groups. 
445 
HES 650/0.42/2.8 HES 650/0.42/5.6 
(n = 15) (n = 15) 
41.3 ::':: 3.8 
93 ::':: 19 
79 ::':: 13 
37.8 ::':: 0.2 
8.6 ::':: 1.1 
22.08 ::':: 3.95 
41 ::':: 3.7* 
81 ::':: 17* 
84 ::':: 18* 
38.2 ::':: 0.2* 
8.1 ::':: 1 * 
20.82 ::':: 5.19* 
•No statistical significant difference when cornpared with hydroxyethyl starch 
(HES) 650/0.42/2.8. 
7.5% using TEG® parameters angle ex and maximal am-
plitude and a SD of 5%, a total sample size of 30 pigs has 
been determined with a type I error of 0.05. The high-
molecular-weight HES solution with the low C2/C6 ratio 
of 2.8 (I-IES 650/0.42/2.8) was compared with the high-
molecular-weight HES solution with the C2/C6 ratio of 
5.6 (HES 650/0.42/5.6) using theJMP 5.1 statistical pack-
age (SAS Institute, Inc, Cary, NC). Data (with and with-
out baseline correction) were analyzed using the Sha-
piro-Wilk test for normality and a two-way analysis of 
variance for repeated measures on one way (time) with 
the Greenhouse-Geisser correction for assessing solution 
and time effects. Pharmacoldnetic parameters obtained 
from mode! fitting were thereafter compared between 
HES 650/0.42/2.8 and HES 650/0.42/5.6 by way of the 
unpaired Student t test. No data transformation was 
applied. Results are expressed as mean :±: SD. 
Results 
In total, 31 animais had to undergo the study protocol 
to complete the investigation in 30 because of erroneous 
HES infusion in one inclividual. There were no differ-
ences between groups at baseline (table 2). 
HES Pbarmacokinetics 
The HES concentrations increased progressively in 
both groups during infusion and decreased from the end 
of infusion until 630 min, following a biexponential 
profile. There were no significant differences between 
the solutions (figs. 2A and B). 
A two-compa1tment mode! for the calculation of the 
HES concentration was able to fit well the concentration 
curves of the solutions, producing an excellent correla-
tion between measured and calculated values (R2 = 
0.991) (fig. 1). 
Hydroxyethyl starch 650/0.42/2.8 had a 29% higher 
elimination constant ke1 than I-IES 650/0.42/5.6 (P < 
0.001). Also compared with this solution, a significantly 
smaller area under the plasma concentration-tune curve 
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was found (19%; P = 0.026). Ali other pharmacokinetic 
parameters showed no significant differences between 
the groups (table 3). 
In vivo, the MWw (P = 0.004) and the MWn (P = 
0.009) were smaller for HES 650/0.42/2.8, compared 
with HES 650/0.42/5.6 (figs. 2C and D). The index of 
polydispersity MWw/MWn revealed no significant differ-
ences between the HES solutions (fig. 2E). 
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Coagulation Analys;s 
Plasma Coagulation Tests. Parameters of plasma co-
agulation such as prothrombin time (seconds), aPTf 
(seconds), and functional FVIII and vWF activity (%) 
changed significantly over time (P < O.OCll for ail), but 
no significant between-group differcnces wcre founcl. 
The maximum effect was reached immediately after the 
end of infusion at 30 min (figs. 3A-D). 
C2/C6 RATIO OF HES AND BLOOD COAGULATION 
Table 3. Pharmacokinetic Parameters 
Cmax cale, g/I 
AUC, min · g/I 
Volume, 1 
CL, 1/min 
t112, min 
k12, min-1 
k21 , min-1 
k0 ,, min-1 
HES 650/0.42/2.8 
(n = 15) 
9.50 ± 1.82 
1,374 ± 340 
6.54 :t: 1.77 
0.057 ± 0.016 
221 ± 37 
0.007 :t 0.005 
0.007 ± 0.003 
0.009 ± 0.001 
HES 650/0.42/5.6 
(n = 15) 
9.50 ± 2.01* 
1,697 ± 411t 
6.77 Je 1.81* 
0.047 ± 0.015* 
238 ± 33* 
0.007 ± 0.002* 
0.008 ± 0.003* 
0.007 ± 0.001 :j: 
Pharmacokinetic parameters of the hydroxyethyl starch (HES) solutions, cal-
culated by a two-compartment mode!: maximal concentration (Cmnxl, area 
under the concentration-lime curve {AUC), distribution volume (Volume), 
clearance (CL), elimination hall-lime (t112), rate constant of transfer from the 
central to the peripheral compartment (k,,), rate constant of transfer from the 
peripheral to the central compartment (k21 ), rate constant of elimination (k,,1). 
Results are shown as mean ± SD. 
* No statistical significant differences, when compared with HES 650/0.42/ 
2.8. t P = 0.026, :j: P < 0.001, when compared with HES 650/0.42/2.8. 
TEG@. Ail TEG@ parameters showed significant time-
dependent alterations after the infusion irrespective of 
the HES solution used (P < 0.001 for ail). The compro-
mising effect on Thrombelastography@ parameters 
reached its maximum at the end of infusion (30 min for 
k time, maximal amplitude, angle œ, coagulation index, 
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and shear elastic moclulus), only for r time the maximum 
was reached after 20 min, during the infusion. No sig-
nificant between-group differences were found in TEGŒ> 
(figs. 4A-F). 
Hemoglobin Concentration 
During the HES administration, the hemoglobin con-
centration decreased continuously from 8.1 ± 1 g/dl to 
5.9 ± 0.6 g/dl (HES 650/0.42/5.6) at the end of the 
infusion (30 min), respectively, and from 8.6 ± 1.1 g/dl 
to 6.2 ± 0.6 g/dl (HES 650/0.42/2.8) (P < 0.001 for all). 
Thereafter, hemoglobin concentration increased pro-
gressively to values close to the baseline values. After 
630 min, the hemoglobin was 7.2 ± 0.9 g/dl for HES 
(650/0.42/5.6) and 7.2 ± 0.7 g/dl for HES (650/0.42/ 
2.8). No significant differences were found between the 
tested solutions (fig. SA). 
AllJumin Concentration 
The albumin concentration showed a similar behavior 
with an initial decrease until the end of infusion fol-
lowed by a subsequent increase without reaching the 
baseline values. No significant differences were found 
between the tested solutions (fig. 5B). 
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Discussion 
The primarir aim of this study was to examine the 
single-close administration of a new high-molecular-
weight, low-substituted HES with a low C2/C6 ratio 
regarcling its pharmacoldnetic profile, compared with a 
reference solution. We founcl that a recluction of the 
C2/C6 ratio from HES 650/0.42/5.6 to HES 650/0.42/2.8 
modifies to some extent the pharmacokinetic profile, 
resulting in lower area uncler the curve surface and 
higher elimination constant for HES 650/0.42/2.8. Re-
garding the global effects, HES 650/0.42/2.8 and HES 
650/0.42/5.6 reach similar levels of absolute concentra-
Anesthc~iol()!,')', V 107, No 3, Sep 2007 
tions, hemoclilutional effect, and alteration of blood co-
agulation, without clifferences between the groups. 
The higher elimination constant found for HES 650/ 
0.42/2.8 and the restùting smaller area under the curve, 
when compared with HES 650/0.42/5.6, confirm the fact 
that the C2/C6 ratio influences the HES clegraclation: The 
higher the C2/C6 ratio, the slower the HES is hydrolyzed 
due to a relative resistance toward c:x-amylolytic attack of 
the C2-linked sicle chains of the molecule. 18•19 Jung et 
at. 20 found a prolongation of the elimination half time 
when increasing the C2/C6 ratio from 4.6 to 10.8, while 
keeping the same molccular weight of 200 kd and molar 
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630 min after stat1: of infusion. • Solution effects of hydroxyethyl stat·ch (RES) 650/0.42/2.8 versus HES 650/0.42/5.6 are determined 
by two-way analysis of variance. 
substitution of 0.5. We found a similar influence of the 
C2/C6 ratio on high-molecular-weight, low-substituted 
HES in the current study, resulting in a decreased blood 
exposure. This indicates that the influence of the C2/C6 
ratio on HES pharmacoldnetics is consistent over a con-
siderable range of molecular weight. However, the range 
of C2/C6 ratio assessed in the current study is limited. To 
verify a general impact of the C2/C6 ratio on HES phar-
macokinetics, a wider range of molar substitution includ-
ing higher-substituted I-IES with molar substitutions of 
up to 0.6 or 0.7 and a wider range of C2/C6 ratios must 
be studied. 
Treib et al. 18 showecl a significant difference regarcling 
the in vivo molecular weight after repeated infusion of 
HES 200/0.5/5.7 and HES 200/0.5/13.4 in patients. In 
that study, the HES with the higher C2/C6 ratio accumu-
lated and had a higher in vivo molecular weight, indi-
cating a slower enzymatic breakdown. Contrarily to this, 
we did not observe higher concentrations 600 min after 
stop of infusion, possibly because of the lower substitu-
tion of the HES used. 21 Also, the lower level of C2/C6 
ratio of the HES used in the current stucly may have 
contributed to a stronger cleavage by the ex amylase. 
Moreover, we administered one single top-load dose 
without any redosing. In another crossover stucly with 
six patients who received either HES 200/0.5/10.8 or 
HES 200/0.5/5.8, the BES with the higher C2/C6 ratio 
had a higher plasma concentration and a higher in vivo 
molecular weight after single-dose administration. 14 
These results are partly confirmecl by our study, as we 
also found significantly higher in vivo molecular weights 
in the HES 650/0.42/5.6 than in the BES 650/0.42/2.8 
group (figs. 2C and D). 
In numerous stuclies, molecular weiglit is measured for 
the first time at the end of infusion. In these stuclies in 
vivo molecular weight is at its maximum at the end of 
infusion and clecreases subsequently.7 ·H,is,22 We there-
fore expected during infusion an in vivo molecular 
weight relatively close to the in vitro molecular weight 
or at least between the in vitro molecular weight and 
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the in vivo molecular weight at the end of infusion (30 
min). However, we founcl that the in vivo molecular 
weight increased cluring infusion to follow the expected 
decrease thereafter, i.e., after the end of infusion at 30 
min (figs. 2C and D). This phenomenon may suggest a 
metabolism mainly directed by ex-amylase activity, which 
is increasingly saturatecl cluring HES infusion. 
It remains to be elucidated whether the smaller area 
uncler the concentration-time cutYe for HES 650/0.42/ 
2.8 compared with BES 650/0.42/5.6 is only due to 
higher intravascular metabolism and elimination rates or 
whether HES with a lower C2/C6 ratio may extravasate 
through the endothelial barrier23 and subsequently be 
degracled by lysosomal ex glycosidase24 or other extravas-
cular mechanisms. 
Moclifying the C2/C6 ratio did not affect the impact on 
blood coagulation (figs. 3 and 4). The major side effect of 
HES is the alteration of blood coagulation, which may be 
a serious limitation to its clinical use, especially in hem-
orrhagic patients or in those with coexisting coagulation 
clisorders.25 This was confirmed by our stucly, as several 
of the coagulation assays reflected the significant alter-
ation of blood coagulation at the end of the BES infusion, 
which might become clinically relevant when usecl in 
humans. But, as mentioned above, molecular weight is 
not the only or the most important determinant of this 
sicle effect of HES. The isolated effect of molecular 
weight on blood coagtùation has been assessed in a 
study using a top-load close pig model, showing that 
high-molecular-weight, low-substitutecl HES (HES 900/ 
0.4 and HES 500/0.4) influence plasma blood coagula-
tion sin1ilarly as low-molecular, low-substituted-weight 
HES (HES 130/0.4).13 The C2/C6 ratio was iclentical for 
these three solutions, as confirmed recently by the man-
ufacturer. Also, the polyclispersity index seems not to 
have a major influence on blood coagulation, because it 
does not represent molar substitution and or C2/C6 
ratio, but only the distribution of molecular weight. 
In combination with standard coagulation assays, 
TEG"" is suitable to get a comprehensive assessment of 
450 
coagulation changes during hemoclilution (in vivo as in 
vitro) and in special clinical situations such as liver 
1 . d d' 9-11,13,26-33 Never transp antat10n an car tac surgery. . . -
theless, TEG® is a global measure of the entire coagula-
tion cascade and is therefore not suitecl to cletect specific 
clefects or deficits of the coagulation factors. However, 
TEG® is useful as a complementary measure to assess 
effects of volume expanders such as HES on clot forma-
tion and firmness. 
The pig moclel is considered suitable for blood coagu-
lation research.34 Coagulation changes under varions 
circumstances can be cletected in the porcine model, 
such as in supraceliac aortic cross clamping, normovol-
emic hemoclilution, and hemo1Thagic shock.35- 37 There 
are differences as compared with the human coagulation 
system: elevated activity of FV, FVIII, FIX, FXI, and FXII 
resulting in a shortened aPTT indicating a slight hyper-
coagulability, 34·38-40 which was confirmed in our study. 
This hypercoagulability of the pig may have masked a 
part of the negative impact on blood coagulation of the 
HES solutions tested, and this may be a limitation of our 
study. However, we were capable of detecting a highly 
significant compromise of blood coagulation due to the 
infusion of HES. The absence of differences between the 
groups thus is not due to a lack: of sensitive measures but 
due to the fact that there is no relevant difference be-
tween the HES solutions tested. In addition, McLoughlin 
et al. 36 have shown that the response of prothrombin 
time and aPTT to profound hemodilution is similar in 
humans and in pigs. Therefore, we may assume that the 
porcine coagulation reacts relatively similar to hemodi-
lution with HES solutions as compared with the human 
coagulation system. 
Hemodilutional effects, as measured by the indirect 
markers hemoglobin and albumin, were not different 
between the study group and the control group (fig. 5). 
This is not a surprising fincling, clespite the fact that the 
area under the time- concentration curves and the elim-
ination constants showed significant clifferences be-
tween the solutions. In fact, water binding capacity is 
related to the number of the osmotically active patti-
cles. 3·5 The number and size of HES molecules in viuo is 
changing constantly over time from the beginning of 
infusion. 3•4 In our study, we confirmecl these finclings: 
HES 650/0.42/2.8 has in vivo significantly lmver molec-
ular weights than HES 650/0.42/5.6 because of the facil-
itated cleavage by a amylase, which results in a cle-
creased area under the curve. Because of the equal 
number of osmotically active particles, the same volume-
expanding effect is mediated by the two HESs (figs. 2B 
and 5). Also, the molar substitution and C2/C6 ratio of 
the HES solution change constantly in the organism and 
could therefore influence the volume-expanding proper-
ties.'" 
Our findings regarcling hemodilution are limited by the 
fact that the study was not specifically designed to di-
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rectly cletect plasma volume- expancling effects. To cle-
termine exactly volume changes in the organism, more 
sophisticated methods must be applied, such as double-
label measurements ofblood volume.23 Beyond this, HES 
650/0.42/2.8 must prove its volume-expanding effect in 
clinical more relevant moclels, such as redosing stucl-
ies 7·18"*1 or animal models of controlled hemorrhage, 
which have been shown to be aclequate for the compar-
ison of the effectiveness of clifferent resuscitation flu-
ids. 42- 46 
W e conclu de that lowering of the C2/C6 ratio of high-
molecular-weight, low-substituted HES 650/0.42/5.6 to 
HES 650/0.42/2.8 results in a fasrer cleavage and elimi-
nation from the intravascular space, without any e-\ri-
dence for a reduction of the volume-expanding effect. 
Because the blood coagulation compromising effect of 
the two solutions was similar, the specific impact of the 
C2/C6 ratio of high-molecular-weight, low-substituted 
starches on blood coagulation seems to be relatively 
small. More research remains to be conclucted with HES 
650/0.42/2.8 to evaluate its clinical benefit. 
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